Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adavosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 known ✓ | P30291 | 20/20 | 1.00 |
| ▸ | PLK1 | P53350 | 6/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | WEE2 | P0C1S8 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | NEK2 | P51955 | 1/20 | 1.00 |
| ▸ | NEK3 | P51956 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adavosertib SCHEMBL30559444 | 1.00 | WEE1 (1.00) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL1504444 | 1.00 | WEE1 (1.00) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL1504996 | 0.99 | WEE1 (0.98) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL1504998 | 0.99 | WEE1 (0.98) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL25890930 | 0.98 | WEE1 (0.96) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL1815951 | 0.97 | WEE1 (0.94) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL3579242 | 0.97 | WEE1 (0.94) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL1811019 | 0.94 | WEE1 (0.89) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL1813967 | 0.94 | WEE1 (0.89) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL15959140 | 0.94 | WEE1 (0.89) | WEE1PLK1PKMYT1GAKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127722-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Engine Biosciences Pte. Ltd. (SG) | 2023-02-08 | — | — | EP | claimed |
| WO-2024059808-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11717505-B2 | Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas | DEL MAR PHARMACEUTICALS (BC) LIMITED (CA) | 2023-08-08 | — | — | US | disclosed |
| CN-116323613-A | Salts and forms of WEE1 inhibitors | 里科瑞尔姆IP控股有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4178960-A1 | SALTS AND FORMS OF A WEE1 INHIBITOR | Recurium IP Holdings, LLC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4127722-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Engine Biosciences Pte. Ltd. (SG) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022251224-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220226277-A1 | DIANHYDROGALACTITOL FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS | DEL MAR PHARMACEUTICALS (BC) LIMITED (CA) | 2022-07-21 | — | — | US | disclosed |
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-06-02 | — | — | US | disclosed |
| US-20220169646-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-06-02 | — | — | US | disclosed |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| US-11332473-B2 | Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors | NUVATION BIO INC. (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2022082174-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11248006-B2 | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226277-A1 | DIANHYDROGALACTITOL FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS | WEE1, WEE2, DCK | WEE1 1/4885PLK1 323/4885PKMYT1 1483/4885 |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | WEE1, WEE2, DPYD | WEE1 1/4885PLK1 222/4885PKMYT1 822/4885 |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | WEE1 1/4885PLK1 576/4885PKMYT1 2007/4885 |
| US-20220169646-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | WEE1 1/4885PLK1 576/4885PKMYT1 2007/4885 |
| US-11717505-B2 | Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas | WEE1, WEE2, DCK | WEE1 1/4885PLK1 323/4885PKMYT1 1483/4885 |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | WEE1 1/4885PLK1 576/4885PKMYT1 2007/4885 |
| US-11248006-B2 | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | WEE1, WEE2, PDPK1 | WEE1 1/4885PLK1 234/4885PKMYT1 897/4885 |
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, VHL | WEE1 1/4885PLK1 703/4885PKMYT1 2463/4885 |
| US-11332473-B2 | Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors | WEE1, WEE2, DPYD | WEE1 1/4885PLK1 222/4885PKMYT1 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.